19 March, 2019
Solna, Sweden – March 19, 2019 – Gesynta Pharma AB (“Gesynta”) today announced that it has signed an asset purchase agreement with Acturum Real Estate AB, under which Gesynta acquires a late-stage drug discovery project, including several proprietary molecules originating from AstraZeneca. The molecules target microsomal Prostaglandin E synthase (mPGES-1), which is involved in the inflammatory processes of cardiovascular diseases and cancer. With this acquisition, Gesynta strengthens its position as a leader in the development of pharmaceutical products inhibiting mPGES-1.
Gesynta’s lead candidate drug, GS-248, is a potent and selective mPGES-1 inhibitor developed for treatment of microvascular diseases in chronic inflammatory conditions. GS-248 is being prepared for clinical development with an expected start of Phase I midyear 2019. The new drug discovery project will broaden the pipeline with potent and promising molecules that will be explored for the treatment of additional cardiovascular diseases and cancer.
“The acquisition of several potent and selective mPGES-1 inhibitors will allow Gesynta Pharma to expand into novel therapeutic indications with high unmet medical need, and to continue the transformation into a multi-program drug development company” says Patric Stenberg, CEO of Gesynta Pharma AB.
For further information, please contact:
Gesynta Pharma AB Patric Stenberg, CEO Tel: + 46 (0)733 836670 E-mail: email@example.com
About Gesynta Pharma AB
Based on research from Karolinska Institutet. Gesynta leverages expertise in arachidonic acid research to explore the use of mPGES-1 inhibition in cardiovascular diseases and cancer. The clinical candidate, GS-248, is an oral small molecule developed for treatment of microvascular disease in chronic inflammatory conditions. When strategically optimal Gesynta will seek pharma partners to efficiently make the new therapies available to patients and to achieve the full commercial potential of its products. Gesynta is a privately held Swedish company located in Stockholm operating with a team of experts in the fields of mPGES-1 medical research, drug discovery and clinical and business development.
Gesynta is located in the Karolinska Institutet Science Park, Sweden and has received support from Karolinska Institutet Innovations AB, NovoNordisk Foundation, Swelife and Vinnova.
For more information, please visit www.gesynta.se.
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our reputable board holds vast experience in drug development, commercialization and company scale-up.
Systemic sclerosis is an autoimmune disease hallmarked by chronic inflammation in the body’s smallest blood vessels.
Half of systemic sclerosis patients develop difficult-to-heal digital ulcers, hampering many everyday activities.
Raynaud’s phenomenon affects most systemic sclerosis patients. It is often the first sign of the disease.
Our lead drug candidate GS-248 is currently under evaluation in a phase 2 study.